An anti-glypican-3 antibody comprising one or more amino acid substitutionsintroduced in the Fc region is disclosed. Preferably, in the anti-glypican-3antibody, one or more of the amino acid residues at the positions 239, 298, 326,330 and 332 in the Fc region are substituted with other amino acid residues. Sincethe Fc-modified anti-glypican-3 antibody of the invention exhibit enhancedADCC activity, it is useful in treating cancers, such as hepatic cancer. Alsodisclosed are an anticancer agent comprising the anti-glypican-3 antibodyof the invention and a pharmaceutically acceptable carrier, as well as a methodof treating a patient with cancer comprising administering to the patient theanticancer agent of the invention.
